Category: Kelun
-
Merck, Kelun buoyed by phase 3 results for breast cancer antibody drug conjugate
•
JHVEPhoto/iStock Editorial via Getty Images Merc (New York Stock Exchange: Merck) and its Sichuan partner Kelun-Biotech reported that phase III data on its antibody drug candidate Sacituzumab tirumotecan (sac-TMT) led to a 69% reduction in the risk of progression or death in people with triple-negative breast cancer. From 233 Of…